Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01216241 · ClinicalTrials.gov registry record · Phase 3

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

A Phase 3 study, sponsored by University of Rochester.

Terminated
Registry status
Phase 3
Development phase
36
Enrollment target

NCT01216241 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01216241, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.

TERMINATED
Registry status
Phase 3
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.

Interventions

  • OTHER Saline Placebo
  • DRUG Daptomycin

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2011-04
Est. Completion 2013-04
Phase Phase 3

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT01216241

The ClinicalTrials.gov registry entry for NCT01216241 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Saline Placebo is the first listed.

NCT01216241 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01216241 about?

NCT01216241 is a clinical study titled "Daptomycin Versus Placebo in Patients With Neutropenia and Fever". The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.

What is the current status of trial NCT01216241?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2011-04. Estimated completion is 2013-04.

What interventions are being tested in trial NCT01216241?

The interventions under investigation include: Saline Placebo (OTHER), Daptomycin (DRUG).

Who is sponsoring clinical trial NCT01216241?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.